These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 31779670)

  • 1. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.
    Ashton NJ; Suárez-Calvet M; Heslegrave A; Hye A; Razquin C; Pastor P; Sanchez-Valle R; Molinuevo JL; Visser PJ; Blennow K; Hodges AK; Zetterberg H
    Alzheimers Res Ther; 2019 Nov; 11(1):94. PubMed ID: 31779670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease.
    Park SH; Lee EH; Kim HJ; Jo S; Lee S; Seo SW; Park HH; Koh SH; Lee JH
    Sci Rep; 2021 Jun; 11(1):13050. PubMed ID: 34158530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.
    Piccio L; Deming Y; Del-Águila JL; Ghezzi L; Holtzman DM; Fagan AM; Fenoglio C; Galimberti D; Borroni B; Cruchaga C
    Acta Neuropathol; 2016 Jun; 131(6):925-33. PubMed ID: 26754641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology.
    Winfree RL; Nolan E; Dumitrescu L; Blennow K; Zetterberg H; Gifford KA; Pechman KR; Seto M; Petyuk VA; Wang Y; Schneider J; Bennett DA; Jefferson AL; Hohman TJ;
    Mol Neurodegener; 2024 May; 19(1):41. PubMed ID: 38760857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TREM2 expression in the brain and biological fluids in prion diseases.
    Diaz-Lucena D; Kruse N; Thüne K; Schmitz M; Villar-Piqué A; da Cunha JEG; Hermann P; López-Pérez Ó; Andrés-Benito P; Ladogana A; Calero M; Vidal E; Riggert J; Pineau H; Sim V; Zetterberg H; Blennow K; Del Río JA; Marín-Moreno A; Espinosa JC; Torres JM; Sánchez-Valle R; Mollenhauer B; Ferrer I; Zerr I; Llorens F
    Acta Neuropathol; 2021 Jun; 141(6):841-859. PubMed ID: 33881612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
    Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The
    Deming Y; Filipello F; Cignarella F; Cantoni C; Hsu S; Mikesell R; Li Z; Del-Aguila JL; Dube U; Farias FG; Bradley J; Budde J; Ibanez L; Fernandez MV; Blennow K; Zetterberg H; Heslegrave A; Johansson PM; Svensson J; Nellgård B; Lleo A; Alcolea D; Clarimon J; Rami L; Molinuevo JL; Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Ewers M; Harari O; Haass C; Brett TJ; Benitez BA; Karch CM; Piccio L; Cruchaga C
    Sci Transl Med; 2019 Aug; 11(505):. PubMed ID: 31413141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF sTREM2 in delirium-relation to Alzheimer's disease CSF biomarkers Aβ42, t-tau and p-tau.
    Henjum K; Quist-Paulsen E; Zetterberg H; Blennow K; Nilsson LNG; Watne LO
    J Neuroinflammation; 2018 Nov; 15(1):304. PubMed ID: 30390679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease.
    Bekris LM; Khrestian M; Dyne E; Shao Y; Pillai JA; Rao SM; Bemiller SM; Lamb B; Fernandez HH; Leverenz JB
    J Neuroimmunol; 2018 Jun; 319():19-27. PubMed ID: 29685286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis.
    Liu D; Cao B; Zhao Y; Huang H; McIntyre RS; Rosenblat JD; Zhou H
    Neurosci Lett; 2018 Nov; 686():10-16. PubMed ID: 30171911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease.
    Zhao A; Jiao Y; Ye G; Kang W; Tan L; Li Y; Deng Y; Liu J;
    J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36519540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble TREM2 Concentrations in the Cerebrospinal Fluid Correlate with the Severity of Neurofibrillary Degeneration, Cognitive Impairment, and Inflammasome Activation in Alzheimer's Disease.
    Španić Popovački E; Babić Leko M; Langer Horvat L; Brgić K; Vogrinc Ž; Boban M; Klepac N; Borovečki F; Šimić G
    Neurol Int; 2023 Jul; 15(3):842-856. PubMed ID: 37489359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid sTREM2 in Alzheimer's disease: comparisons between clinical presentation and AT classification.
    Knapskog AB; Henjum K; Idland AV; Eldholm RS; Persson K; Saltvedt I; Watne LO; Engedal K; Nilsson LNG
    Sci Rep; 2020 Sep; 10(1):15886. PubMed ID: 32985583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers.
    Del-Aguila JL; Benitez BA; Li Z; Dube U; Mihindukulasuriya KA; Budde JP; Farias FHG; Fernández MV; Ibanez L; Jiang S; Perrin RJ; Cairns NJ; Morris JC; Harari O; Cruchaga C
    Mol Neurodegener; 2019 May; 14(1):18. PubMed ID: 31068200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer's disease.
    Wang L; Nykänen NP; Western D; Gorijala P; Timsina J; Li F; Wang Z; Ali M; Yang C; Liu M; Brock W; Marquié M; Boada M; Alvarez I; Aguilar M; Pastor P; Ruiz A; Puerta R; Orellana A; Rutledge J; Oh H; Greicius MD; Le Guen Y; Perrin RJ; Wyss-Coray T; Jefferson A; Hohman TJ; Graff-Radford N; Mori H; Goate A; Levin J; Sung YJ; Cruchaga C
    Mol Neurodegener; 2024 Jan; 19(1):1. PubMed ID: 38172904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TREM2 ectodomain and its soluble form in Alzheimer's disease.
    Yang J; Fu Z; Zhang X; Xiong M; Meng L; Zhang Z
    J Neuroinflammation; 2020 Jul; 17(1):204. PubMed ID: 32635934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide association study identifies Alzheimer's risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels.
    Hou XH; Bi YL; Tan MS; Xu W; Li JQ; Shen XN; Dou KX; Tan CC; Tan L; ; Yu JT
    Neurobiol Aging; 2019 Dec; 84():241.e13-241.e20. PubMed ID: 31204042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.